This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving HDR-BT may be effective in providing local control while reducing side effects in patients with prostate cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of grade 2 or greater genitourinary adverse events (AEs)
Timeframe: Up to 6 years
Incidence of grade 2 or greater gastrointestinal AEs
Timeframe: Up to 6 years
Time to first grade 2 or greater adverse event
Timeframe: Up to 6 years
Local control rate
Timeframe: Up to 6 years